Wednesday, July 20, 2016 5:28:43 PM
JULY 20, 2016 BY TERRY DAWES
Dr. Gary Kobinger
The Infectious Disease Research Centre (IDRC) ( http://www.cri.ulaval.ca/en/ ) and the Centre de recherche du CHU (Centre hospitalier de l’Université) ( http://www.crchudequebec.ulaval.ca/en ) at Laval University are set to begin the first clinical study for a Zika vaccine in Canada, after getting regulatory approval from Health Canada and the U.S. Food and Drug Administration to begin Phase I clinical trials.
The 16-month trial is a partnership with the University of Pennsylvania, which will also see testing on a group of human subjects, while 10-15 volunteers will participate in the trials at Laval.
“There is no existing treatment or vaccine for Zika,” said Gertrude Bourdon, president and CEO of CHU. “The vaccine currently being developed will be administered to humans for the first time as part of the clinical study. CHU de Québec-Université Laval is one of the three leading research centres involved in the vaccine study and we’re very proud of that.”
The vaccine, which has the working name GLS-5700, will be made by Inovio, based in Plymouth Meeting, Pennsylvania, and GeneOne Life Science, of Seoul, South Korea.
A so-called DNA vaccine, it is delivered into the site of injection on the skin via a short electrical pulse that propels the DNA, which has been coded to produce the protein that surrounds the Zika virus, to seek out human cells through a process called electroporation.
Ideally, the cells fight back by training the immune system to recognize the Zika virus as a foreign invader, and generating antibodies to fight it.
Inovio has indicated that its testing of the vaccine on mice and monkeys successfully triggered a robust antibody response.
Dr. Sylvie Trottier will lead the Quebec City team, under guidance from Gary Kobinger.
“We’re very proud to be part of the first international team in the world to complete all of the steps in the regulatory process and to be authorized by the Food and Drug Administration (FDA) and Health Canada to develop a Zika vaccine,” said Kobinger, doctor of microbiology, professor in Université Laval’s Faculty of Medicine, researcher with Centre de recherche du CHU, director of IDRC, and a global authority on vaccine research.
Kobinger has previous experience overseeing the optimization of the experimental Ebola treatment ZMapp at the National Microbiology Laboratory in Winnipeg.
At the moment, 18 companies and research organizations are known to be racing to develop Zika virus vaccines, including French pharmaceutical giant Sanofi SA in partnership with the U.S. Army, India’s Bharat Biotech, and the National Institute of Allergy and Infectious Diseases.
The Zika virus, which has been traveling quickly through South America and the Caribbean, is transmitted primarily by mosquito.
The World Health Organization forecasts a sharp increase in Zika infections, up to four million people, and that the virus constitutes a public health emergency, given that it causes birth defects.
The WHO says that ongoing transmission of the Zika virus has been reported in 61 countries and territories, and that 12 countries and territories have already reported Zika-related birth defects.
Women infected by the virus are at risk of either miscarrying or giving birth to children with microcephaly, a condition characterized by infants with abnormally shaped heads, although most cases of Zika under normal circumstances are relatively mild.
If all goes well with the Phase I trial, it should enter Phase II trials using a larger group of volunteer subjects in early 2017. Even so, it will be at least two years before a vaccine is available for mass distribution to patients.
The research team at the Infectious Disease Research Centre, contactable by phone at 418-654-2796, is currently looking for healthy adult volunteers to participate in the study.
http://www.cantechletter.com/2016/07/zika-virus-vaccine-phase-clinical-trial-humans-set-begin-quebec-city/
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM